The discussion features founders from two longevity companies, New Limit and Until, who are pursuing complementary strategies: epigenetic reprogramming to "reset" cellular age and cryopreservation to "pause" time, respectively.
Artificial intelligence is presented as a critical catalyst for both companies, enabling at least a 2x acceleration in R&D by navigating vast, combinatorial biological search spaces that are intractable for human researchers.
New Limit is developing medicines to restore youthful function to cells, has identified its first preclinical candidate, and uses AI in an active learning loop to discover effective combinations of transcription factors.
Until is focused on solving the organ transplant crisis through reversible cryopreservation, with a long-term vision of creating hibernation pods for whole organisms to bridge the gap to future medical cures.
8 quotes
Concerns Raised
The immense combinatorial complexity of biological systems
The high risk and capital intensity of long-term R&D projects
The long and arduous drug approval process (10+ years)
The difficulty of establishing clear 'halting criteria' for research projects
Opportunities Identified
Using AI and active learning to dramatically accelerate the pace of biological discovery
Developing epigenetic reprogramming as a new therapeutic modality to treat age-related diseases
Solving the organ transplant crisis with reversible cryopreservation
Reversing Eroom's Law and reducing the cost of drug development